⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IVVD News
Invivyd, Inc. Common Stock
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
IVVD
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
globenewswire.com
IVVD
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
globenewswire.com
IVVD
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
globenewswire.com
IVVD
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
globenewswire.com
IVVD
Adimab Records Another Year of Double-Digit Clinical Program Growth
prnewswire.com
GSK
BIIB
NVS
BMY
REGN
VRTX
LLY
MRK
ALNY
IVVD
ALE
SCHR
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
globenewswire.com
IVVD
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
globenewswire.com
IVVD
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
globenewswire.com
IVVD
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
globenewswire.com
IVVD